Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data [Seeking Alpha]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Seeking Alpha
End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Mind Medicine Overview The last time I wrote about Mind Medicine (MindMed) Inc. NASDAQ: MNMD ) was when it was gearing up to report results from a phase 2b study known as MMED008, which was using its drug MM120 for the treatment of patients with generalized anxiety disorder [GAD]. This was in a prior Seeking Alpha article entitled " Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts. " I believe it is important to prov
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- MindMed to Present at Upcoming May Medical ConferencesBusiness Wire
- This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' [Yahoo! Finance]Yahoo! Finance
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $20.00 price target on the stock.MarketBeat
MNMD
Earnings
- 11/2/23 - Beat
MNMD
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- MNMD's page on the SEC website